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SUPPLEMENT ARTICLE
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Abstract
Background: Allergies to cats are the most common animal‐origin allergy, and affect
approximately 1 in 5 adults worldwide. The prevalence of allergy to furry animals
has been increasing, and allergy to cats is a major risk factor for the development of
asthma and rhinitis. The diagnosis of cat allergy is now well established. The exact
significance of component‐resolved diagnosis in the diagnosis of cat allergy remains
to be fully understood. Allergen avoidance is effective but often has a psychologic
impact. Allergen immunotherapy is not well demonstrated. There is a need for inno‐
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vative approaches to better manage cat allergens. Next‐generation care pathways for
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asthma and rhinitis will define the place of cat allergen avoidance.
Academy of Allergy and Clinical Immunology Congress 2019, provides information
on the prevalence and impact of cat allergies and the molecular biology of Fel d 1,
the major cat allergen.
Discussion: The authors present the scientific basis of a novel care pathway that
utilizes anti‐Fel d 1 IgY antibodies to safely and effectively neutralize Fel d 1 after its
production by the cat but before human exposure.
Conclusion: Efficacy of a feline diet with an egg product ingredient containing anti‐
Fel d 1 IgY antibodies was demonstrated in vitro, ex vivo, and in vivo, and further vali‐
dated by a pilot exposure study involving cat‐allergic human participants.
KEYWORDS

allergens, anti‐Fel d1 IgY, blocking antibodies, cat allergies, Fel d 1

1 | I NTRO D U C TI O N

sensitization to cats and 60%‐90% of the overall antigenicity of cats
and cat dander.2,5-9

Allergies to cats are the most common mammalian‐origin allergy in

Traditional care pathways for cat allergies focus on treating pa‐

humans1-3 and affect approximately 1 in 5 adults worldwide.4,5 Fel d 1

tients who are exposed to cat allergens. The following review ex‐

is the major cat allergen, accounting for up to 96% of human allergic

pands on information presented during a sponsored symposium at

Abbreviations: AIT, allergen immunotherapy; AR, allergic rhinitis; ARIA, Allergic Rhinitis
and its Impact on Asthma; BAMSE, Swedish abbreviation for Children, Allergy, Milieu,
Stockholm, Epidemiology; ICP, Integrated care pathway; POLLAR, Impact of air
POLLution on Asthma and Rhinitis; SCIT, Subcutaneous immunotherapy; SLIT, Sublingual
immunotherapy.

the European Academy of Allergy and Clinical Immunology (EAACI)
Annual Congress on June 4, 2019, in Lisbon, Portugal. The sympo‐
sium, titled “Keep the cat, changes the care pathway: a transfor‐
mational approach to managing cat allergy,” presented a research

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited and is not used for commercial purposes.
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breakthrough that reduces cat allergens while maintaining normal

diameter. 2

9

It is passively transferred on clothing 2,5,19; as a result,

production of Fel d 1 by the cat and without impacting the cat's

the allergen is ubiquitous and has been documented in homes with‐

overall physiology. This new approach provides an opportunity for a

out cats, private vehicles, and public transportation and buildings

novel clinical care pathway that allows the cat to remain in the home.

at levels (≥8 µg Fel d 1 per gram of dust) that exceed threshold
value associated with sensitization. 2,5,7,25-34 Although Fel d 1 levels

2 | FE L D1 , TH E M A J O R C AT A LLE RG E N

in schools are detectable, they are often low and may not induce
symptoms, 35 but a Swedish study found that indirect exposure
to cat may be associated with worsening of asthma in cat‐allergic

To date, eight cat‐origin allergens have been identified and regis‐

students. 26

tered through the World Health Organization/International Union
of Immunological Societies (WHO/IUIS) Allergen Nomenclature
Sub‐Committee. 2,10-12 Fel d 1, a secretoglobin, is the major cat al‐
lergen. 2,5-9,13 (Table 1) Although monosensitization to Fel d 1 is com‐

2.1 | Fel d 1‐induced sensitization and IgE‐
mediated allergy

mon, individuals sensitized to the cat allergens Fel d 2 (an albumin

Upon initial exposure to an allergen (such as Fel d 1), antigen‐present‐

allergen) and Fel d 4 (a lipocalin allergen) are usually also sensitized

ing cells (eg, dendritic cells and macrophages) capture and process the

to Fel d 1.3 Fel d 1 is a sufficiently dominant allergen that IgE sen‐

allergen, then present antigenic peptides to T helper cells. Stimulated

sitization to Fel d 1 is equivalent to cat extract in predicting cat

by the presence of specific cytokines (eg, interleukin‐4, interleu‐

allergy.

3,13,14

kin‐13), the T helper cells acquire a type 2 phenotype (Th2) and recruit

All cats produce Fel d 1 regardless of breed, age, hair length, sex,

B lymphocytes to produce and secrete IgE.36-38 The Th2 phenotype

housing (indoors vs outdoors), or body weight; there are no allergen‐

is thought to have evolved as a response to helminth parasites, but

free or hypoallergenic cats.2,9,15-19 Fel d 1 production varies widely

also plays a beneficial role in a number of physiologic functions.37

among individual cats and may vary widely throughout the year in

Excessive or mis‐targeted Th2 cell responses may result in allergic re‐

the same cat.15,16,20 Bastien et al16 observed an 80‐fold difference in

sponses, including atopy, allergic rhinitis, and allergic asthma.37

salivary Fel d 1 levels between the lowest‐producing and highest‐pro‐

The allergen‐specific IgE binds to high‐affinity immunoglobulin

ducing cats in a 64‐cat group and up to a 76‐fold difference between

receptors (FcϵRI; considered high‐affinity because their affinity for

the lowest and highest salivary Fel d 1 levels in individual cats. Studies

IgE is 100 times greater for IgE than for IgG) on the surface of mast

have shown that male cats produce 3‐5 times less Fel d 1 after neuter‐

cells and basophils to create allergen‐specific receptors.38,39 Very

ing; these findings, combined with observations that Fel d 1 produc‐

little IgE is found in the circulation as soluble IgE.40

tion could be restored to preneutering levels with the administration

Mast cells, located in mucosal and epithelial tissues near poten‐

of exogenous testosterone, suggest an influential role of testosterone

tial points of allergen entry into the body (such as the respiratory

on Fel d 1 production.1,2,21,22

tract mucosa), play a critical role in the allergic response.40 With sub‐

Fel d 1 is produced primarily in the salivary and sebaceous glands

sequent exposure to the allergen following sensitization, the allergen

and in lesser amounts in the lacrimal and anal glands.2,23 It is spread

binds to and crosslinks two or more IgE:FcϵRI complexes on mast

throughout the cat's hair during grooming and shed into the environ‐

cells, triggering degranulation, and the release of inflammatory me‐

ment with hair and dander.2,17 Fel d 1's biological function for the cat

diators (eg, histamine; heparin; interleukins 3, 4, and 5; leukotrienes,

is as yet unknown, but a pheromone/chemical signaling role has been

prostaglandins, thromboxanes).38-42 Inhaled allergens, such as Fel d

proposed.

2,5,22,24

1, induce mast cell activation in the respiratory tract, resulting in

Fel d 1 easily becomes and remains airborne in dander and dust

symptoms of airway constriction, increased mucous production, and

particles; up to 60% of Fel d 1 is carried by particles <5 microns in

coughing.40 These mediators also attract additional cells that amplify
the inflammatory response, creating a potentially self‐propagating

TA B L E 1 Human sensitization rates to feline‐origin allergens.
(Excerpted from EAACI Molecular Allergology User's Guide, 2016.)
Allergen

Biochemical name

Human sensitization rate

Fel d1

Uteroglobin

60%‐100%

Fel d2

Serum albumin

14%‐54%

Fel d3

Cystatin

10%

Fel d4

Lipocalin

63%

Fel d5

Immunoglobulin A

38%

Fel d6

Immunoglobulin M

unknown

Fel d7

Lipocalin

38%

Fel d8

Latherin‐like protein

19%

inflammatory cycle.40

3 | C AT A LLE RG I E S : A CO M M O N
PRO B LE M W ITH CO N S EQ U E N C E S FO R
H U M A N S A N D C AT S
The prevalence of allergy to furry animals has been increasing, and al‐
lergy to cats is a major risk factor for the development of asthma and
rhinitis.43 The diagnosis of cat allergy is now well established.9 Allergen
avoidance is effective, but often has a psychologic impact. Allergen
immunotherapy (AIT) is not well demonstrated.44 There is a need for
innovative approaches to better manage cat allergy.
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3.1 | Prevalence

3.3 | The allergic burden

Most people in Western societies spend over 90% of their lives in‐

Classical symptoms of cat allergy include rhinitis, asthma, and/or

door, and indoor allergens play an important role in allergic sensitiza‐

conjunctivitis. Quality of life is impaired in patients with allergic rhi‐

tion and symptoms. The percentage of homes with a pet ranges from

nitis (AR) or asthma, who may suffer from poor quality sleep, fatigue,

around 5% in Spain, 20% in Sweden, 25% in the United States, and

reduced alertness, lower work productivity and concentration,

up to 65% in New Zealand.9,43,45

and mood changes.53-55 Learning may be impaired in children with

Allergies to cat affect 7%‐25% of the population and represent a
growing public health concern as these rates increase.

3,7,9

allergic rhinitis.53 The direct costs to the allergy sufferer are com‐

The prev‐

pounded by the indirect costs to society of impaired productivity

alence of cat allergy varies between countries, timing of exposure,

and performance.56 The severity of AR symptoms is the most com‐

9

and allergic predisposition. Cat allergy is found both in developed

mon factor associated with impairment of productivity, but AR‐re‐

and developing countries,46,47 starts early in infancy and progresses

lated sleep disturbances may contribute to the issue.56 According to

13,48

up to young adulthood,

and can be observed in children who live

in a house where cats are not present.

49

a digitally based mobile health (mHealth) initiative, 90% of app users
with uncontrolled AR experienced some work productivity impair‐
ment and over 50% experienced severe work impairment. 56 These

3.2 | Mono‐ and polysensitization
Cross‐reactivity or co‐sensitization exists between some animal aller‐

impairments may result not only from the allergic condition itself,
but also from undesired effects of medications taken for symptom
prevention and relief.53,57

gens, and many patients are allergic to cats and dogs, but also to other

In addition to their role in AR, allergies to cats and dogs are a

furry animals. However, since the major cat allergen Fel d 1 does not

major risk factor in the development of asthma.7,19,47,58 It is esti‐

cross‐reacts with other animals, co‐sensitization is more likely.

mated that pets are the third‐leading cause of IgE‐mediated allergic

13

sensitizations to Fel d 1 in childhood

asthma. Cat‐allergic children experience twice as many days with

were significantly associated with symptoms to cat at age 16 years.

In the BAMSE cohort,

asthma symptoms and require more frequent dosing of β‐agonists

Polysensitization to 3 or more allergen molecules from cat was a bet‐

and steroids during the second week of the school term in class‐

ter longitudinal predictor of cat symptoms than results of IgE tests

rooms with moderate‐to‐high prevalence of home cat ownership. 26

with cat allergen extract. Cross‐sectionally, cat‐polysensitized chil‐

More than 500 000 emergency visits were attributed to cat aller‐

dren had higher IgE levels and more frequent symptoms to cat than

gen‐induced asthma attacks in a cat‐sensitive and exposed popula‐

monosensitized children.

tion of patients with asthma.58

In the West Sweden Asthma Study, the characterization of sen‐

The psychologic impact of cat allergy is of great concern. Many

sitization to furry animal allergen components was assessed in an

patients or parents of allergic children fail to comply with their physi‐

adult population.3 Fel d 1 was the most prevalent cat component in

cian's recommendations to avoid the animal; this can be understood

monosensitized individuals, whereas all cat allergens including Fel d

especially when there are emotional consequences to making the

1 were detected in polysensitized individuals. This study may be of

asked for lifestyle changes.

relevance for the stratification of patients who would be exposed to
low‐allergencity cats.
Sensitization to furry animal allergen components is an import‐
ant predictor of asthma, rhinitis, and markers of asthma severity.50

3.4 | Allergy's impact on cat welfare and the human‐
animal bond

Current asthma and asthma symptoms following contact with cats

Pet ownership confers numerous health benefits, including positive

were associated with co‐sensitization to Fel d 1 and Fel d 4. This

influences on blood pressure and cardiovascular health, loneliness,

association was seen already at moderate‐level sensitization (1‐15

depression and mental health, and weight management. 59 Many

ISU) to Fel d 4, at which level most children were sensitized to Fel

owners consider their cats part of the family.45,59-63 For these rea‐

d 1, as well.51 There is a wide heterogeneity among cat‐allergic in‐

sons, allergists' guidelines‐based recommendations to remove the

dividuals with multiple clusters of sensitization. Each sensitization

cat from the home are often met with resistance.8,9,19,64

cluster (nonsensitized, Fel d 1‐driven sensitized, and multisensitized

Allergies can limit the interactions between the allergic person

clusters) was associated with substantial increased risk of asthma,

and their cat, interfering with the human‐animal bond. According

rhinitis, concomitant asthma, and rhinitis.50 There was, however,

to the American Veterinary Medical Association, the human‐animal

no association with asthma exacerbations, FEV1 predicted values,

bond is described as “a mutually beneficial and dynamic relationship

emergency visits, or regular oral steroid use. In another study, chil‐

between people and animals that is influenced by behaviors essential

dren with severe allergic asthma had higher serum IgE levels to cat,

to both. This includes, among other things, emotional, psychological,

dog, and horse. Molecular‐based allergy diagnostics revealed a more

and physical interactions of people, animals and the environment.”65

complex molecular spreading of allergen components (polysensitiza‐

Physical contact plays an important role in the strength and longev‐

tion) in children with the most severe disease.52

ity of the human‐cat bond.66,67 Many cat owners, and particularly
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female owners, also value their cat's cleanliness60; understanding

not; however, multiple allergens present at subthreshold levels may

that grooming is an important aspect of cleanliness as well as a pri‐

have a cumulative effect that exceeds the threshold and triggers the

mary method for dispersion of cat allergens throughout the cat's hair

chain of events leading to allergic symptoms.40 The number of IgE

and subsequently into the environment, this highly desired behav‐

receptors bound, not the identity of the allergen(s), determine if the

ioral feature facilitates allergen exposure for allergic individuals.

process is initiated.

Allergy to cats directly impacts cat welfare because allergy is

If the allergen load can be reduced by avoiding or reducing the

a commonly provided reason for relinquishment of cats to shel‐

level of exposure to one or more of the contributing allergens, the

ters,68-72 as well as a barrier to cat adoption and ownership.72,73

cumulative level of allergen exposure may fall below an individual's
threshold and improve or prevent allergy symptoms.40,75

3.5 | Diagnosis of cat allergy
The diagnosis of cat allergy is based on symptoms occurring during
exposure and the demonstration of an IgE‐mediated sensitization to
9

4.1.1 | Avoidance
Removing the cat from the home is the most commonly recom‐

cat allergens. Skin prick tests with standardized extracts are reli‐

mended measure, although it is not supported by evidence.8,9,19,77

able. Serum‐specific IgE with a crude extract is equally important.

Fel d 1 is a “sticky” allergen, and it may take months for symptoms to

However, the results of these tests should be confronted to symp‐

improve following removal of the cat from the household, particu‐

toms as they only indicate a cat sensitization.

larly if the household is carpeted.78,79 Wood et al79 observed that up

Most recently, molecular‐based (component‐resolved) diagnosis
has become available. However, its exact significance in the diagnosis

to 20 weeks were required following removal of the cat for Fel d 1
levels to reduce to those found in homes without cats.

of cat allergy remains to be fully understood.74 On the other hand, for

On the other hand, it is suggested that symptomatic patients may

the prediction of asthma severity50,51 or persistence to symptoms,13

become tolerant to the cat after some months of continuous expo‐

molecular‐based diagnosis may be relevant. One major advantage of

sure and a specific IgG4 response is associated with tolerance.80

the current molecular‐based diagnosis is certainly the determination

Tolerance duration is, however, unknown, and many adults who had

of the primary sensitization source, which is not feasible by using ex‐

cats in childhood may develop severe asthmatic reactions when re‐

tracts. This implies, of course, a better management of allergic patients.

exposed to cats many years later.

Exposure tests are not recommended in routine diagnosis of cat
allergy.9

So‐called “hypoallergenic pets” have been marketed to allergy
sufferers, but their clinical relevance has never been demon‐
strated.9,18 Although patents have been filed for gene editing to

4 | CU R R E NT M A N AG E M E NT

produce allergen‐free cats and the topic has received intermittent
media attention for more than a decade, the truly allergen‐free cat
has been elusive.81

Several recommendations have been proposed to reduce cat aller‐
genicity, but to date, none of them present convincing evidence.

4.1 | Allergen load reduction
Polysensitized individuals will often show more severe symptoms

4.1.2 | Environmental control
Environmental control measures are also recommended in order to
reduce environmental allergen levels, and measures implemented in
cat‐sensitized households may include the following:

than monosensitized individuals when exposed to environmental al‐
lergens, indicating that allergens have an additive effect.40,75 This

• Excluding the cat from the bedroom8,9,19,82

reinforces the concept of total allergen load, which represents the

• Keeping the cat outdoors8

sum of the individual allergens in the environment at that time. If

• Use of HEPA filters in vacuums and HVAC systems8,9,19,83,84

the total allergen load exceeds an individual's allergic threshold, that

• Removal of carpets8,79,82

individual develops allergic symptoms.

• Using pillow and mattress covers9,82

The total allergen load and allergic threshold represent the clini‐

• Removal or covering of upholstered furniture9,79

cal manifestation of the underlying molecular process: similar to the

• Weekly vacuuming or steam cleaning79,82

allergic threshold associated with an individual, mast cells and baso‐

• Wet mopping floors and surfaces82

phils bearing the IgE receptors have a threshold at which degranu‐

• Washing walls82

lation and mediator release are triggered. The cellular threshold has

• Ventilation to increase air change rate per hour85

been estimated to required crosslinking of 2000 out of an estimated

• Changing clothes before moving from an area of high allergen lev‐

500 000‐1 000 000 high‐affinity IgE receptor complexes on the cell
surface.

40,76

High exposure levels of one allergen may be sufficient

to trigger degranulation and mediator release, while lower levels do

els to one with lower levels8
• Using nighttime laminar airflow ventilation9,78
• Regular bathing of cats in the home2,9,86,87
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Allergists' recommendations may include washing the cat to phys‐
ically remove allergens from its hair.2,9,86,87 This recommendation

9

4.4 | Primary Prevention

has poor compliance,82 due largely to the feline species' aversion

The role of pet keeping in early life to prevent cat allergy is still a mat‐

to bathing. In addition, although immersion bathing is effective

ter of debate. Early exposure to pets before 1 year of age may have a

for lowering allergen levels on the cat's hair, the effects of bathing

protective effect in preventing allergic sensitizations, but studies to

are transient; allergen levels return to baseline within 24 hours of

date have produced conflicting results. However, a meta‐analysis from

bathing.2,86,87

11 pooled European birth cohorts concluded that there was no evi‐

Although these measures may reduce the allergen load, 82 they

dence for a protective or “harmful” effect of cat ownership on sensiti‐

are effort‐intensive, costly, and may be difficult to sustain long

zation.95 To date, there is no consensus regarding animal exposure and

term.77 In addition, the effects may be transient. 8,19 Multifaceted

preventing later onset of asthma or other allergic diseases.

interventions are recommended for best results. 8,9 Because Fel
d 1 is such a ubiquitous allergen, sensitized individuals that suc‐
cessfully reduce the allergen load in their own homes will still
be exposed to potentially high levels of cat allergens at work, in
homes of cat‐owning family members or friends, and in public
places. 2,5,7,25-32
Perinasal mechanical barriers are intended to entrap airborne al‐

5 | N E X T‐ G E N E R ATI O N C A R E PATH WAYS
O F C AT A LLE RG Y
5.1 | Care pathways in the digital transformation of
health

lergens and prevent them from contacting the respiratory mucosa. A

Integrated care pathways (ICPs) are structured multi‐disciplinary

hydroxypropyl methylcellulose barrier had positive effects on nasal

care plans detailing the key steps of patient care.96 They promote

symptom score, ocular symptom score, total symptom score, and qual‐

the translation of guideline recommendations into local protocols

ity of life score in patients with perennial and seasonal AR.88

and their application to clinical practice. An ICP forms all or part
of the clinical record, documents the care given, and facilitates
the evaluation of outcomes for continuous quality improvement.97

4.2 | Pharmaceutical interventions

They empower patients as well as their health and social carers.

There is no specificity for the treatment of symptoms induced by cats.

ICPs differ from practice guidelines as they are utilized by a

However, patients with a known cat allergy may prevent the onset of

multi‐disciplinary team and focus on the quality and co‐ordination of

symptoms by using medications before cat exposure. Rapidly acting

care. ICPs need to record variations from planned care.98 An ICP is

medications are favored for both asthma and rhinitis.

89

intended to inform and encourage thought and adaptation. Clinicians
are free to exercise their own professional judgments as appropri‐
ate. However, any alteration to the practice identified within this ICP

4.3 | Immunotherapy

must be noted as a variance.99 Variance analysis may be used to op‐

Davila et al recommended that immunotherapy with cat epithelium

timize the ICPs linked with pay‐for‐performance (P4P),100-103 audit

would be indicated in patients with allergic respiratory disease under

and feedback, and integration of recommendations with electronic

circumstances in which there is exposure, assessing the viability and

medical records.

9

efficacy of environmental control measures, drug therapy, and patient

ICPs are already the standard of care in different areas of med‐

preferences. However, there is a limited body of high‐quality evidence

icine such as oncology104 or palliative care.105 Some have already

on the effectiveness and safety of cat AIT from large randomized con‐

been proposed for asthma or COPD.

trolled trials either for subcutaneous (SCIT) or for sublingual immu‐

There is a need to support the digital transformation of health

notherapy (SLIT) and no high‐quality data on its cost‐effectiveness.44

and care with ICPs. ICPs have been proposed with a focus on

Around 200 patients have been enrolled in double‐blind trials for SCIT,

mHealth technologies that should enhance self‐management and

and results are inconsistent. The available evidence on effectiveness is

adherence to guidelines and ICPs. An innovative patient‐centered

mixed based on studying a limited array of immunological, physiologi‐

approach for ICPs has been proposed by the ARIA expert group for

cal, and patient‐reported outcome measures. Based on this evidence

rhinitis and asthma multi‐morbidity.56,106-109

and extrapolating on the wider evidence base in AIT, it is likely that
some patients may benefit from this modality of treatment, particu‐
larly those with moderate‐to‐severe disease who are inadequately
controlled on allergen avoidance measures and pharmacotherapy and

5.2 | Multisectoral care pathways for
rhinitis and asthma

those who are monosensitized to Fel d 1. Further evidence is, how‐

A large number of AR patients do not consult physicians because

ever, required from larger trials before more definitive advice can be

they think their AR symptoms are “normal” and/or trivial. However,
AR negatively impacts social life, school, and work productivity.110

44

offered.

Many trials with T‐cell peptides have shown limited efficacy and/

Many AR patients use over the counter (OTC) drugs and only a frac‐

or led to nonimmediate allergic reactions during treatment90-92 al‐

tion have had a medical consultation.111 The vast majority of patients

93,94

though immunologic effects were demonstrated.

who visit general practitioners or specialists have moderate/severe
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F I G U R E 1 Multi‐disciplinary approach as proposed by
AIRWAYS ICPs [Color figure can be viewed at wileyonlinelibrary.
com]

F I G U R E 2 Fel d 1 crystalline (A) and three‐dimensional (B)
structures, showing four subunits composed of two covalently
linked heterodimers containing two distinct chains. From https://
www.rcsb.org/structure/2EJN, open source image [Color figure can
be viewed at wileyonlinelibrary.com]

rhinitis.112-116 Thus, ICPs should consider a multi‐disciplinary ap‐
proach as proposed by AIRWAYS ICPs (Figure 1).

proposed modifications has not, to the authors' knowledge, been
investigated.
Novel strategies have been developed to treat Fel d 1‐induced

5.3 | Next‐generation care pathways for rhinitis and
asthma using ICP

allergy in human subjects by immunizing cats against their own

Although environmental factors play a major role in allergic diseases,

Fel d 1 and a virus‐like particle derived from the cucumber mosaic

no guideline or recommendation has included them. Based on the

virus containing the tetanus toxin‐derived universal T‐cell epitope

results of POLLAR (Impact of air pollution on asthma and rhinitis, 55

major allergen.120 A conjugate vaccine consisting of recombinant

tt830‐843 (CuMV TT ) was used to immunize cats. All cats induced a

ARIA next‐generation ICPs will embed exposure to environmental

strong and sustained specific IgG antibody response. The induced

factors like pollen and air pollution as well as novel approaches like

anti‐Fel d 1 antibodies were of high affinity and exhibited a strong

artificial intelligence that have not been considered up to now. As

neutralization ability tested both in vitro and in vivo. A reduction in

there is increasing evidence that patients' choices and behaviors

the endogenous allergen level and a reduced allergenicity of tear

have an impact on the planet, this will be the background of ARIA

samples were observed.120 However, clinical studies are needed to

117

Planetary Health.

confirm the approach.

Another interesting approach is to propose nonmedical approaches

Because the biological function of Fel d 1 for the cat is cur‐

to control allergic symptoms. In all allergy textbooks, allergen avoid‐

rently unknown, the potential health and welfare effects of ceasing

ance is always required but most studies failed to prove efficacy for

its production are also unknown; for this reason, we sought to de‐

house dust mites. However, new data in stratified severe asthmatic pa‐

velop an approach that does not alter the cat's production of Fel d

118

tients are encouraging.

In cat allergy, a reduction in cat allergenicity

1. It is understood that patients receiving immunotherapy develop

can represent a revolution in the management of cat‐allergic patients

“blocking antibodies” (usually IgG) which help to prevent the allergic

and next‐generation care pathways should recognize the results of the

cascade38; therefore, our research hypothesized that it could be pos‐

studies when they will be completed. Whether a patient stratification

sible to use a similar process to neutralize the Fel d 1 allergen after

is needed should be further established.

its production by the cat but before its activation of allergy effector
cells. This approach attempts to reduce allergenic (active) Fel d 1 by

6 | N EU TR A LIZ I N G FE L D 1 AT IT S
S O U RC E
Anecdotal evidence has suggested that altering a cat's diet may

binding the allergen with anti‐Fel d 1 polyclonal egg IgY antibodies.

6.1 | Effective neutralization of Fel d1 requires
binding at multiple epitopes

affect allergen production, but specific nutritional interventions

Fel d 1 is a four‐subunit (tetrameric) protein composed of two co‐

have not been evaluated using the scientific method. Pezzali et

valently linked heterodimers, each of which contains two distinct

al119 postulated that dietary modification to reduce sebum pro‐

chains (Chain 1, a polypeptide, and Chain 2, a glycopeptide with

duction may lower Fel d 1 production by cats: possible modifica‐

N‐linked oligosaccharides) that are encoded by separate genes and

tions included isoflavones and phytoestrogens to reduce androgen

linked with disulfide bridges. 2,10,11,24,121-127 (Figure 2) Despite varia‐

production; reducing the omega‐6/omega‐3 fatty acid ratio in the

tion in Fel d 1 due to differential gene expression for the two chains,

diet; and reducing the glycemic index of the cat's diet by lower‐

core fragments are preserved and the structural variation in Fel d 1

ing carbohydrate levels.119 However, the clinical efficacy of their

has a low impact on its allergenicity.125
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The three‐dimensional structure of Fel d 1 is unique and com‐

manner similar to the Indoor Poly polyclonal antibody in both

2

the modified chimeric ELISA and basophil activation assay.133

plex, with an internal cavity and two external calcium‐binding sites.

The heterodimer structure is important in allergenicity of Fel d 1

(Figure 3).

because IgE reactivity directed against the individual chains is far
less than the level of reactivity against the heterodimer, suggesting
the importance of protein conformation in Fel d 1‐IgE binding. 2,7,128
Reduction and alkylation eliminate Fel d 1's allergenic activity, fur‐

6.3 | Anti‐Fel d 1 IgY effectively neutralizes active
Fel d 1 in vivo

ther suggesting conformation‐dependent IgE binding sites.7,129

Building on the previous in vitro and ex vivo studies, the next step in

Three epitopes were identified on Fel d 1: two epitopes on Chain 1

the investigative process was to determine whether the anti‐Fel d 1

130,131

and one epitope on Chain 2.

More recently, Tasaniyananda et

IgY produced effective Fel d 1 blocking in cats in vivo.

al132 identified spatially juxtaposed residues on Chain 1 that indicate
an additional epitope on that chain.
Monoclonal antibodies against Fel d 1 do not effectively neu‐
tralize the allergen's ability to induce an immune response. A com‐

6.4 | Feline test diet with added anti‐Fel d 1 IgY
reduces active Fel d 1 in saliva

mercially produced rabbit‐origin anti‐Fel d 1 monoclonal antibody

Based on the in vitro and ex vivo study results, it was hypothesized

(Fel d 1 major allergen 1 polypeptide chain 1 antibody, product

that feeding cats anti‐Fel d 1 IgY would reduce immunologically ac‐

no. FELD1‐121AP, FabGennix) (FGI) did not prevent binding of Fel

tive (allergenic) Fel d 1 (active Fel d 1; aFel d 1) in cat saliva. In a

133

In con‐

pilot study, saliva was collected (Salivette®) from six healthy, adult

trast, a commercially produced rabbit antiserum containing poly‐

d 1 to Fel d 1‐specific IgE in a modified chimeric ELISA.

domestic shorthair cats before their morning feeding and at 1, 3, and

clonal antibodies to Fel d 1 (Rabbit anti‐Fel d 1 (PA‐FD1), Indoor

5 hours postfeeding. All of the cats received a control diet (without

Biotechnologies) (Indoor Poly) was able to bind several epitopes on

anti‐Fel d 1 IgY) for a 2‐week baseline period, followed by 6 weeks

the Fel d 1 molecule and successfully blocked Fel d 1 binding to IgE

on the test diet (control diet with added anti‐Fel d 1 IgY). A signifi‐

in vitro in a dose‐dependent manner.133

cant decrease in salivary aFel d 1 was detected within 2 weeks of

Monoclonal and polyclonal anti‐Fel d 1 antibodies were pre‐incu‐
bated with cat saliva and evaluated utilizing a humanized rat basophil

starting the test food, and the average decrease over the 6‐week
treatment period was 29.57%.136

cell line and a beta‐hexosaminidase assay to indicate degranulation

In the second trial in the study, saliva was collected from twenty

and mediator release. The polyclonal antibody reduced mediator re‐

healthy, adult domestic shorthair cats 5 hours after their morning

lease in a dose‐dependent fashion but the monoclonal antibody had

feeding, 5 days a week for the duration of the 5‐week study. Cats

no blocking action on mediator release.133

were fed a control diet for a 1‐week baseline period, followed by

These findings are consistent with those of Orengo et al,

38

who

either the control diet (control group) or the control diet with an egg

observed that monoclonal antibodies against Fel d 1 did not effec‐

product containing anti‐Fel d 1 IgY (test group) for 4 weeks. Salivary

tively block IgE and mast cell degranulation in basophil activation

aFel d 1 was significantly reduced by Week 3 in the cats receiving

assay, but a combination of monoclonal antibodies directed at dif‐

the anti‐Fel d 1 IgY in their diet, with a mean reduction of 24%, while

ferent epitopes—resulting in simulated polyclonal binding to Fel d

the control group did not show any significant reduction in active Fel

1—was effective. The simulated polyclonal antibody combination

d 1 with a mean reduction of only 4%.136 (Figure 4).

also blocked cutaneous anaphylaxis in a mouse model, confirming
that multiple epitopes must be bound to prevent Fel d 1‐induced IgE
crosslinking and cellular activation.38

6.2 | Anti‐Fel d 1 IgY effectively neutralizes active
Fel d 1 in vitro and ex vivo
Based on the findings that polyclonal binding is necessary to neu‐
tralize Fel d 1's allergenicity, Satyaraj et al133 evaluated the effi‐
cacy of avian egg yolk‐derived immunoglobulin Y (IgY) directed
against Fel d 1. IgY is an avian equivalent to mammalian IgG and is
found in chicken serum and egg yolks. Chickens naturally produce
IgY against environmental antigens and transfer the IgY into their
eggs to provide passive immunity to their offspring.134,135 Anti‐Fel
d 1 IgY can be induced by exposing hens to Fel d 1. Based on this
principle, anti‐Fel d 1 IgY were produced using well‐established
immunization methods.133 Anti‐Fel d 1 IgY blocked the binding of
salivary Fel d 1 to Fel d 1‐specific IgE in vitro in a dose‐dependent

F I G U R E 3 Beta‐hexosaminidase assay results from eggs from
blocking experiments using eggs from chickens immunized to Fel
d 1 to produce anti‐Fel d 1 IgY (immune) and eggs from the same
chickens prior to Fel d 1 exposure (pre‐immune). β‐hexosaminidase
levels are expressed as percentages of baseline levels from control
samples incubated without antibodies [Color figure can be viewed
at wileyonlinelibrary.com]
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This study demonstrated that a diet with egg product ingredient
containing anti‐Fel d 1 IgY effectively reduced salivary aFel d 1 levels
of cats.

6.5 | Feline test diet with added anti‐Fel d 1 IgY
reduces Fel d 1 in hair and dander
Previous studies demonstrated that anti‐Fel d 1 IgY blocked IgE‐me‐
diated degranulation in vitro and ex vivo and significantly reduced
salivary aFel d 1 levels in cats in vivo. Fel d 1 enters the environment
through shed hair and dander; therefore, the next step in the valida‐
tion process was to determine the effects of anti‐Fel d 1 IgY on aFel
d 1 levels in the cat's hair and dander.
Hair was collected (by brushing) from 105 healthy domestic
shorthair cats four times over a 2‐week baseline period, then weekly
during a 10‐week treatment period during which the cats received
a food with an egg product ingredient containing anti‐Fel d 1 IgY.

F I G U R E 5 Active Fel d 1 levels (µg/g hair) means and SE across
weeks. Means were significantly reduced from baseline at week
1 (P < .05) and weeks 3 through 10 (P < .001) using linear mixed
effect models and P‐value adjustments using the single‐step
method Columns with the lighter color denote values that were
statistically different from baseline (Source: CC BY 3.0, Satyaraj et
al, 2019137) [Color figure can be viewed at wileyonlinelibrary.com]

Active Fel d 1 levels in the hair and dander collected by brushing
were significantly reduced starting in Week 3 of the treatment pe‐
riod and remained at reduced levels for the remainder of the treat‐
ment period. The aFel d 1 reduction ranged from 31% to 77%, with
an average aFel d 1 reduction of 47%.137 (Figure 5) Cats with the
highest baseline aFel d 1 levels showed the greatest decrease in aFel
d 1 during the treatment period. (Figure 6).
This study demonstrated that a diet with egg product ingredient
containing anti‐Fel d 1 IgY effectively reduced aFel d 1 levels in the
hair and dander of cats.

6.6 | Anti‐Fel d 1 IgY is safe for cats

allergies.64 However, although many allergic owners will compromise
their own health to keep their cat, they are unlikely to accept ap‐
proaches that they feel may put their cat's health and well‐being at
risk.
All egg products with egg yolk contain IgY. Egg products con‐
taining specifically targeted IgY have been used safely in human and
veterinary medicine.138-141 The anti‐Fel d 1 IgY is safe for cats, based
on a comprehensive safety study that fed an egg product ingredient
with multiple levels of anti‐Fel d 1 IgY, including levels many times
higher than those used in efficacy studies.142

Many cat owners view their cats as part of the family45,60-62 and
will often go to great lengths to keep their cat in the home despite

F I G U R E 4 Reduction in salivary active Fel d 1 levels (µg/mL)
in response to a diet with an egg product ingredient containing
anti‐Fel d 1 IgY. The line with circle data points depicts data
from the control diet group and the line with triangle data points
depicts data from the test diet group. Asterisks denote statistical
significance (P < .05) compared with baseline based on linear mixed
model analysis (Source: CC‐BY‐NC Satyaraj et al, 2019136) [Color
figure can be viewed at wileyonlinelibrary.com]

F I G U R E 6 Change in active Fel d 1 (µg/g hair) means over time
based on initial concentrations. Cats were divided into quartiles
based on their baseline aFel d 1 levels and linear regression was
used to estimate the initial level (intercept) and the change in aFel
d 1 over time (slope). The graph represents a total of 1470 samples
obtained during the 12‐week study. The slope of decline in aFel d 1
levels was significantly steeper for those cats in the highest quartile
(P < .001) but did not differ among the three lower quartiles
(P > .1) based on ANOVA with Tukey Post hoc Tests. Cats with the
highest Fel d 1 production showed the greatest response to the
intervention (Source: CC BY 3.0, Satyaraj et al, 2019137) [Color
figure can be viewed at wileyonlinelibrary.com]
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Based on the principle of allergen load reduction, complete elimi‐

nonsignificant trends toward improvement. Although the TOSS score

nation of Fel d 1 production is not necessary. Our approach does not

was not significantly reduced, the mixed model analysis showed that

neutralize 100% of the cat's Fel d 1; in essence, it converts moderate

the subscores for itchy eyes and scratchy eyes were significantly im‐

and high Fel d 1‐producing cats to the equivalent of low or moder‐

proved for the test exposures, but not the control exposures, when

ate producers without altering the cat's production of the allergen.

compared to priming exposures.143

Cats produce varying levels of Fel d 1 depending on neuter status,

This pilot study demonstrated that feeding cats a diet with an egg

sex, and genetics and can be healthy regardless of their Fel d 1 lev‐

product ingredient containing anti‐Fel d 1 IgY decreases the environ‐

els15,121; our approach preserves some biologically available Fel d 1

mental Fel d 1 levels in a controlled environment and produces a sig‐

while reducing the active allergen.

nificant improvement in Total Nasal Symptom Score and some ocular
symptoms in cat‐allergic human subjects. Further research is indicated

6.7 | Clinical impact of anti‐Fel d 1 IgY

to determine the efficacy of anti‐Fel d 1 IgY in a home setting.

Reducing the levels of active Fel d 1 in a cat's saliva and hair can re‐
duce the amount of cat allergens shed into the environment on hair

7 | CO N C LU S I O N

and dander, thereby reducing the total allergen load in the environ‐
ment. If the allergen load is reduced to a level below the individu‐

When presented with a cat‐allergic, cat‐owning patient, allergists are

al's allergic threshold, clinical allergy symptoms may be prevented.

often compelled to recommend removal of the cat from the home in

In order to determine the effects of feeding cats a diet with an egg

order to reduce the environmental allergen load and relieve clinical

product containing anti‐Fel d 1 IgY on clinical symptoms in human

symptoms of allergy. However, this recommendation is often met with

allergy sufferers, a controlled exposure study was conducted.143

resistance because cat owners consider their cats to be members of

Volunteer participants (n = 114) were screened for the study.

the family and are not willing to re‐home or relinquish their cat. A new

Subjects with asthma were excluded. Subjects were screened and

approach, using anti‐Fel d 1 IgY incorporated into the cat's food, re‐

selected for participation if they met the following criteria: history

duces immunologically active Fel d 1 in the cat's saliva and on their

of strong cat sensitivity; positive skin prick test to standardized cat

shed hair and dander, ultimately reducing active Fel d 1 in the envi‐

allergen extract; and documented variable response to high vs low

ronment and improving clinical symptoms in cat‐sensitized individuals.

levels of Fel d 1 on preliminary testing. Eleven subjects met all crite‐

This approach offers healthcare providers an opportunity to reframe

ria and completed the study.

their conversations with cat‐allergic patients, allowing a focus on pro‐

Eight healthy, domestic shorthair cats were fed either a control diet
(n = 4) or a test diet (n = 4) composed of the control diet with added egg

active measures without the emotional toll associated with recom‐
mending the removal of a beloved cat from the home.

product ingredient containing anti‐Fel d 1 IgY for 8 weeks. During the
last 4 weeks of the study, blankets used by the cats as bedding were
collected and used to load the chambers described below.
Portable greenhouse chambers (SpringHouse Clear Growth,
FlowerHouse, Inc.) were used as individual exposure chambers to
provide a controlled environment for the study. Each chamber was
loaded with a blanket (as previously described) from either a control
diet‐fed cat (control exposure) or a test diet‐fed cat (test exposure);
a fan to circulate air within the chamber; a chair for the participant;
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and a Petri dish to collect settled dust to determine Fel d1 levels
within the chamber.
Participants underwent a priming exposure with high Fel d 1 levels
to prime the immune response to the allergen and establish a bench‐
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mark for comparison, followed by random assignment to either the
control or the test exposure the following week and the opposite ex‐
posure 2 weeks later. Exposures lasted 3 hours or until symptoms be‐
came intolerable, and patients recorded their symptoms and severity
on a Total Nasal Symptom Score (TNSS) and Total Ocular Symptom
Score (TOSS) sheet every 15 minutes during the exposure.
TNSS values were significantly reduced in test exposures com‐
pared with the priming exposure, but the scores were not statisti‐
cally different between the priming and control exposures. Mixed
model analysis demonstrated that nasal congestion subscores were
significantly improved, and other subscores of the TNSS showed
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